Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > BUSINESS
BUSINESS
- Novartis Launches Diovan OD Tablets, Sales Reps Find Promotion Difficult
July 24, 2013
- Astagraf XL, Tacrolimus Extended-Release Capsules, Approved in US: Astellas
July 24, 2013
- Kyowa Kirin Files Poteligeo for PTCL, CTCL in Japan
July 23, 2013
- Toho University Prof. Nakamura Says Prasugrel Promising in Preventing Platelet Clotting
July 22, 2013
- AD Treatment Lu AE58054 Improves Cognitive Performance in PII Study: Otsuka Pharmaceutical
July 22, 2013
- AD Biomarker TOMM40 Favorable in Detecting AD Risk: Takeda
July 19, 2013
- Xtandi Share May Increase as Second-Line Drug in US, Ranks Top as Third-Line Drug: Kantar Health
July 19, 2013
- Teribone’s Sales Growing Fast, Owing to High Demand of Drugs Promoting Bone Formation: Asahi Kasei Pharma President
July 19, 2013
- 60% Generic Share Target Is Highly Achievable: Daiichi Sankyo Espha President Yoshiwaka
July 19, 2013
- Novartis to Share Ex-Employee Hearing Info, Says “Gravely Concerned” about Media Reports
July 18, 2013
- Pfizer Paid 23.9 Billion Yen to Physicians, Medical Institutions in FY2012; 1st Disclosure under JPMA Guidelines
July 18, 2013
- BIKEN, JPRI to Merge in April
July 18, 2013
- MTPC to Strengthen Vaccine Development through Merger with Canadian Biotech Company Medicago
July 18, 2013
- Mylan Generics Will Be Distributed under Pfizer Brand Next Year: Pfizer’s Matsumori
July 17, 2013
- GSK Withdraws COPD Indication from NDA for ICS/LABA Combination Drug in Japan
July 17, 2013
- Astellas Launches Anticancer Agent Xtandi in UK
July 16, 2013
- Hisamitsu Initiates Domestic PII Study of Long-Acting Transdermal Allergic Rhinitis Treatment
July 16, 2013
- Manipulation of Data Cannot Be Confirmed Based on Results of University’s Investigation: Novartis Pharma
July 16, 2013
- Nippon Chemiphar Considers Establishing Manufacturing Base in Vietnam
July 16, 2013
- Otsuka Forms Clinical Research Firm in UK as Europe’s R&D Hub
July 12, 2013
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…